AAA
CERE
Affinity Asset Advisors’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-500,000
| Closed | -$20.4M | – | 105 |
|
|
2024
Q2 | $20.4M | Buy |
500,000
+200,000
| +67% | +$8.18M | 2.36% | 7 |
|
|
2024
Q1 | $12.7M | Sell |
300,000
-450,000
| -60% | -$19M | 1.57% | 16 |
|
|
2023
Q4 | $31.8M | Buy |
750,000
+64,939
| +9% | +$2.75M | 5.81% | 2 |
|
|
2023
Q3 | $15M | Buy |
685,061
+135,061
| +25% | +$2.95M | 4.21% | 5 |
|
|
2023
Q2 | $17.5M | Buy |
550,000
+170,000
| +45% | +$5.4M | 6.11% | 2 |
|
|
2023
Q1 | $9.27M | Buy |
380,000
+165,000
| +77% | +$4.02M | 3.06% | 7 |
|
|
2022
Q4 | $6.78M | Buy |
+215,000
| New | +$6.78M | 2.66% | 13 |
|
|
2022
Q2 | – | Sell |
-70,000
| Closed | -$2.45M | – | 64 |
|
|
2022
Q1 | $2.45M | Sell |
70,000
-155,000
| -69% | -$5.43M | 0.39% | 29 |
|
|
2021
Q4 | $7.3M | Sell |
225,000
-34,966
| -13% | -$1.13M | 2.65% | 12 |
|
|
2021
Q3 | $7.67M | Buy |
259,966
+59,966
| +30% | +$1.77M | 1.94% | 7 |
|
|
2021
Q2 | $5.12M | Sell |
200,000
-70,000
| -26% | -$1.79M | 1.83% | 14 |
|
|
2021
Q1 | $3.71M | Hold |
270,000
| – | – | 1.26% | 16 |
|
|
2020
Q4 | $4.48M | Buy |
+270,000
| New | +$4.48M | 2.37% | 9 |
|